UCB SA: 1 director

A director at UCB SA bought 70 shares at 250.000EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...

Hybrid Software Group Strong 3Q update; record sales in Enterprise Sof...

Hybrid Software Group published their limited 3Q trading update. After a tough 1H25, the company has turned the page with a significant uptick in sales and, more importantly, very strong margins. At these levels HYSG is well on track to beat our FY operating & net result estimates. We keep our TP on €5.0 for now and comfortably reiterate our Buy recommendation.

UCB - Slowing Bimzelx Momentum - D/G to Hold ( TP EUR 250 [270], 14pgs...

For access to the full note, please contact Naresh Chouhan ( )

Morning Notes : ASM NA, UCB BB, SHUR BB

: ASM NA, UCB BB, SHUR BB

UCB Publishes Fintepla LGS open-label extension results in journal

UCB announced that the final analysis of an open-label extension (OLE) study on Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS) was published in the Epilepsy and Behavior journal. This follows previous presentations at a medical conference and highlights the long-term sustained benefit and lack of new or unexpected safety signals, which we view as supportive of Fintepla's benefit in this patient population. For reference, Fintepla is one of UCB's 5 growth drivers, and we estimate peak s...

UCB Publishes pyrimidine nucleo(s)(t)ide therapy results in TK2d in jo...

UCB announced the publication of results from a multicenter retrospective chart review study of pyrimidine nucleo(s)(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d) in Neurology, which are in line with previous reports of the positive outcomes on survival and functional outcomes presented at a medical conference earlier this year. Note that TK2d is an ultra-rare genetic mitochondrial disease with no approved therapies, and has a prevalence of 1.64 per 1m people. Doxecitine an...

Morning Notes : UCB BB, VGP BB, ONWD BB

: UCB BB, VGP BB, ONWD BB

Morning Notes : CPINV BB, CMBT BB, NN NA, MAAT FP

: CPINV BB, CMBT BB, NN NA, MAAT FP

MaaT Pharma Safety board recommends MaaT033 phase 2b continues as plan...

MaaT announced that the independent data safety monitoring board (DSMB) has completed the second pre-planned safety interim analysis of the ongoing randomised controlled phase 2b (PHOEBUS) trial of MaaT033 (microbiome therapy, oral capsule) in patients undergoing an allogeneic hematopoietic stem cell transplantation (allo-HSCT), and recommended that the study continue as planned. There were no safety concerns and no excessive mortality related to MaaT033 as of today. The upcoming routine DSMB re...

Benelux Morning Notes

AB InBev: On Track. UCB: Galvokimig, an opportunity for long-term growth

Morning Notes : AGFB BB, OPTI BB, EVS BB, TINC BB, UCB BB, CTPNV NA

: AGFB BB, OPTI BB, EVS BB, TINC BB, UCB BB, CTPNV NA

UCB Galvokimig R&D call highlights potential in AD, model update

Yesterday, UCB hosted an R&D call to highlight the phase 2a data for galvokimig from EADV 2025, which showed strong efficacy in atopic dermatitis (AD), with a 52.6% placebo-adjusted EASI75 response at week 12, outperforming other biologics in cross-trial comparison. The KOL highlighted galvokimig's potential for broad positioning across the AD treatment paradigm if the early data is replicated in later stage trials, especially as a monotherapy. We update our model for UCB, which brings us to a n...

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 09/29/2025

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 29/09/2025

Benelux Morning Notes

Kendrion: Divests remaining automotive business. UCB: Competitor Sonelokimab fails to impress in HS

Morning Notes : JEN BB, NEXTA BB, PNL NA, UCB BB, MRUS US

: JEN BB, NEXTA BB, PNL NA, UCB BB, MRUS US

UCB Bimzelx competitor sonelokimab shows mixed phase 3 results in HS

In UCB related news, MoonLake Therapeutics (no coverage) reported topline phase 3 data for Bimzelx competitor, sonelokimab (IL-17A/F nanobody) in hidradenitis suppurativa (HS) that showed mixed results. Averaging both VELA-1 and VELA-2 trials brings us to a 13.5% placebo adjusted HiSCR75 response, which is lower than the 17.5% that Bimzelx showed in BE HEARD I and II, and the approx. 20% delta bar set by MoonLake's management earlier this year. Acknowledging the high placebo response in VELA-2, ...

UCB : Further potential for Bimzelx

UCB : Bimzelx peut encore voir venir

Benelux Morning Notes

Aedifica: €21m investment in the development of 3 care homes in Finland. CTP: Highlights from 2-day CMD in Germany. dsm-firmenich: Softly does it. Prosus: Expanding the ecosystem. Randstad: Preliminary preview 3Q25F results due 22 October. TKH Group: Change is coming. UCB: Renewed tariff threat on US branded pharma unlikely to affect UCB